Radiopharm Theranostics Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-5.5%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$2.62next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| RAD 202 and RAD 204 Phase 1 Dose Escalation Completion | 31 Dec 2026 |
| RAD 101 Phase 3 Registrational Trial Readiness | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
RAD 101 Phase 2b Concordance Rate Quarterly90.0%Target: >= 90% concordance with MRI
Cash and Cash Equivalents (A$ Millions) Quarterly19.2Target: Maintain sufficient runway into 2027
RAD 202 Phase 1 HEAT Trial Dose Level Quarterly130.0Target: Complete Phase 1 dose escalation by end of 2026
Watch Items
- RAD 101 Phase 2b Full Data ReadoutTrigger: Concordance rate drops below 90% or safety signals emergeAction: Re-evaluate Phase 3 registrational trial design and potential standalone commercialization or partnering strategy.
- RAD 202 and RAD 204 Phase 1 Dose Escalation ProgressTrigger: Failure to complete Phase 1 dose escalation by the end of 2026Action: Assess clinical trial site performance, patient recruitment rates, and potential protocol amendments.
- Cash Burn Rate and Capital RunwayTrigger: Cash balance falls below A$15 million without a clear path to R&D Tax Incentive receipt or equity financingAction: Initiate strategic partnering discussions or execute additional capital raises to extend runway beyond 2027.
Research as of 20 Jun 2026